The Effect of EDTA Chelation Therapy in Symptomatic Coronary Heart Disease: An Observational Study

Chulananda D. A. Goonasekera, Rohini Tennakoon, Premil N. Rajakrishna, Gammadegedara A. Gunasena, Chandima R. Wanniarachchi, Asanka B. Yatawatta, Udawatta A. D. D. Munidasa

.

DOI: 10.4236/cm.2010.12010                

Abstract

Ethylene Diamine Tetra Acetic Acid (EDTA) chelation therapy has been considered a definitive alternative therapy for by-pass surgery in atherosclerotic cardiovascular disease for more than four decades. It is a relatively inexpensive method believed to restore blood flow in atherosclerotic vessels. However, the benefits of chelation therapy yet remain controversial in the treatment of ischemic heart disease. We observed the effect of EDTA chelation therapy on exercise tolerance in 13 volunteering patients receiving conventional treatment for established symptomatic coronary heart disease. Each patient received 30 weekly infusions of EDTA followed by monthly 12 boosters according to the ACAM protocol (American College for Advancement in Medicine). This was in addition to the conventional therapies they received from their respective physician in hospital. Stress ECG, echocardiography and coronary angiogram findings were obtained at the beginning of treatment. The distance that a patient could walk on level ground at moderate speed and the number of steps he/she can climb up on a staircase until he/she begins to feel either chest pain or breathlessness were the two clinical parameters of exercise tolerance recorded to grade angina. Liver and renal functions were tested at 1st, 5th, 10th, 15th and 30th infusions. Of the 13 patients, 11 showed improvement in angina grading whilst 2 experienced no effect. One patient improved from angina grade IV to I, 6 from grade III to I, 1 from grade III to II and 3 from grade II to I. A statistically significant reduction in the mean score (p = 0.002) was noticed at 6th month of treatment when compared to that of the first month. A significant 1.7 fold increase (p = 0.009) in the mean SGPT level was observed at the 30th infusion when compared to the pre-treatment values. The SGOT level showed no significant change (p = 0.664). None of the patients showed clinical features of hepato-cellular damage. The mean serum creatinine level showed a trend for reduction (p = 0.083) with treatment. The recognized side effects of intravenous EDTA chelation therapy such as liver damage, renal damage, hypersensitivity, symptomatic hypocalcaemia, and thrombophlebitis were not encountered. Thus, EDTA chelation therapy as prescribed by the ACAM protocol seems safe and effective in improving exercise tolerance in ischemic heart disease when administered concurrently with conventional therapy.

Keywords

EDTA Chelation Therapy, Coronary Heart Disease, Exercise Tolerance

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	World Health Organization, “Mortality Country Fact Sheet,” 2006. http://www.who.int/whosis/mort/profiles/mort_searo_ lka_srilanka.pdf
[2]	NCCAM, National Institutes of Health, “Questions and Answers: The NIH Trial of EDTA Chelation Therapy for Coronary Artery Disease,” 2004. http://nccam.nih.gov/ health/chelation/q-and-a.htm
[3]	G. Kindness and J. P. Frackleton, “Effect of Ethylene Diamine Tetra Acetic Acid (EDTA) and Platelet Aggregation in Human Blood,” Journal of Advancement in Medicine, Vol. 2, No. 4, 1989, pp. 519-530.
[4]	L. Chappell and J. P. Stahl, “The Correlation between EDTA Chelation Therapy and Improvement in Cardiovascular Function: A Meta Analysis,” Journal of Advancement in Medicine, Vol. 6, No. 3, 1993, pp. 139-160.
[5]	M. L. Knudtson, D. G. Wyse, P. D. Galbraith, R. Brant, K. Hildebrand, D. Paterson and D. Richardson, “Chelation Therapy for Ischemic Heart Disease: A Randomized Controlled Trial,” Journal of the American Medical Association, Vol. 287, No. 4, 23-30 January 2002, pp. 481- 486.
[6]	“Critique of the Calgary PATCH EDTA Chelation Study,” Adapted from a report by Croft Woodruff in Canada, 2007. http://www.drcranton.com/calgarystudy.htm
[7]	E. Ernst, “Chelation Therapy for Coronary Heart Disease: An Overview of All Clinical Investigations,” American Heart Journal, Vol. 140, No. 1, July 2000, pp. 139-141.
[8]	E. M. Cranton, “Protocol of the American College of Advancement in Medicine for the Safe and Effective Administration of EDTA Chelation Therapy”. Journal of Advancement in Medicine, Vol. 2, No. 1-2, 1989, pp 269- 305.
[9]	E. Ernst, “Chelation Therapy for Coronary Heart Disease: An Overview of All Clinical Investigations,” American Heart Journal, Vol. 140, No. 1, July 2000, pp. 139-141.
[10]	J. S. Shrihari, A. Roy, D. Prabhakaran and K. S. Reddy, “Role of EDTA Chelation Therapy in Cardiovascular Diseases,” National Medical Journal of India, Vol. 19, No. 1, January-February 2006, pp. 24-26.
[11]	P. M. Kidd, “Integrative Cardiac Revitalization: Bypass Surgery, Angioplasty, and Chelation. Benefits, Risks, and Limitations,” Alternative Medicine Review, Vol. 3, No. 1, February 1998, pp. 4-17.
[12]	H. Quan, W. A. Ghali, M. J. Verhoef, C. M. Norris, P. D. Galbraith and M. L. Knudtson, “Use of Chelation Therapy after Coronary Angiography,” American Journal of Medicine, Vol. 111, No. 9, 15 December 2001, pp. 686- 691.
[13]	D. M. Seely, P. Wu and E. J. Mills, “EDTA Chelation Therapy for Cardiovascular Disease: A Systematic Review,” BMC Cardiovascular Disorders, Vol. 5, 2005, p. 32.
[14]	L. Campeau, “Grading of Angina Pectoris,” Circulation, Vol. 54, No. 3, September 1976, pp. 522-523.
[15]	E. W. McDonagh, C. J. Rudolph, E. Cheraskin and D. G. Wussow, “The Effect of EDTA Chelation and Supportive Multivitamin/Trace Mineral Supplementation with and without Physical Activity upon Systolic Blood Pressure” Journal of Orthomolecular Psychiatry, Vol. 13, 1984, pp. 1-9.
[16]	E. M. Cranton and J. P. Frackelton, “Current Status of EDTA Chelation Therapy in Occlusive Arterial Disease,” 2001. http://www.drcranton.com/chelation/emcjpf.htm
[17]	R. Yamamoto, T. Kawamura, K. Wakai, Y. Ichihara, T. Anno and Y. Mizuno, “Favorable Life-Style Modification and Attenuation of Cardiovascular Risk Factors,” Japanese Circulation Society, Vol. 63, No. 3, March 1999, pp. 184-188.
[18]	“EDTA Chelation: The Real ‘Miracle’ Therapy for Vascular Diseases,” Journal of Life Enhancement, 1997. http:// www.life-enhancement.com/article_template.asp?ID=78
[19]	H. R. Casdorph, “EDTA Chelation Therapy, Efficacy in Arteriosclerotic Heart Disease,” Journal of Holistic Medicine, Vol. 3, No. 1, 1981, pp. 53-59.
[20]	M. Elmer and E. M. Cranton, “Protocol of the American College for Advancement in Medicine for the Safe and Effective Administration of EDTA Chelation Therapy,” Journal of Advancement in Medicine, Vol. 2, No. 1-2, 1989, pp. 269-303.